ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1RPRX | ROYALTY PHARMA PLC | Healthcare | $39.56B | 14.90% |
2RVMD | REVOLUTION MEDICINES INC | Healthcare | $38.14B | 14.37% |
3THC | TENET HEALTHCARE CORP | Healthcare | $22.83B | 8.60% |
4NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.15B | 6.46% |
5EXEL | EXELIXIS INC | Healthcare | $17.04B | 6.42% |
6KYMR | KYMERA THERAPEUTICS INC | Healthcare | $10.86B | 4.09% |
7PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $8.77B | 3.30% |
8CORT | CORCEPT THERAPEUTICS INC | Healthcare | $8.07B | 3.04% |
9ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $6.66B | 2.51% |
10IBRX | IMMUNITYBIO INC | Healthcare | $6.46B | 2.43% |
11SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $5.27B | 1.98% |
12DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.21B | 1.96% |
13TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $4.95B | 1.86% |
14IONS | IONIS PHARMACEUTICALS INC | Healthcare | $4.55B | 1.71% |
15CRSP | CRISPR THERAPEUTICS AG | Healthcare | $4.13B | 1.56% |
16RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.99B | 1.50% |
17ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $3.80B | 1.43% |
18NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.30B | 1.24% |
19IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.04B | 1.15% |
20DNLI | DENALI THERAPEUTICS INC | Healthcare | $3.03B | 1.14% |
21XNCR | XENCOR INC | Healthcare | $2.86B | 1.08% |
22RCUS | ARCUS BIOSCIENCES INC | Healthcare | $2.56B | 0.96% |
23BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.49B | 0.94% |
24CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.24B | 0.84% |
25VIR | VIR BIOTECHNOLOGY INC | Healthcare | $2.08B | 0.78% |
26SEPN | SEPTERNA INC | Healthcare | $1.99B | 0.75% |
27BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $1.98B | 0.74% |
28MAZE | MAZE THERAPEUTICS INC | Healthcare | $1.97B | 0.74% |
29ZBIO | ZENAS BIOPHARMA INC | Healthcare | $1.87B | 0.71% |
30ZYME | ZYMEWORKS INC | Healthcare | $1.83B | 0.69% |
31STOK | STOKE THERAPEUTICS INC | Healthcare | $1.71B | 0.65% |
32NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.64% |
33IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.57B | 0.59% |
34ABSI | ABSCI CORP | Healthcare | $1.57B | 0.59% |
35RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $1.53B | 0.58% |
36NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.48B | 0.56% |
37ANAB | ANAPTYSBIO INC | Healthcare | $1.43B | 0.54% |
38KRSA | KORSANA BIOSCIENCES INC | Healthcare | $1.42B | 0.54% |
39OMER | OMEROS CORP | Healthcare | $1.30B | 0.49% |
40NKTR | NEKTAR THERAPEUTICS | Healthcare | $1.27B | 0.48% |
41MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $844M | 0.32% |
42GLUE | MONTE ROSA THERAPEUTICS INC | Healthcare | $796M | 0.30% |
43ALMS | ALUMIS INC | Healthcare | $793M | 0.30% |
44JANX | JANUX THERAPEUTICS INC | Healthcare | $703M | 0.26% |
45KURA | KURA ONCOLOGY INC | Healthcare | $683M | 0.26% |
46AVBP | ARRIVENT BIOPHARMA INC | Healthcare | $676M | 0.25% |
47FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $669M | 0.25% |
48SRZN | SURROZEN INC | Healthcare | $604M | 0.23% |
49CBIO | CRESCENT BIOPHARMA INC | Healthcare | $534M | 0.20% |
50OBIO | ORCHESTRA BIOMED HOLDINGS INC | Healthcare | $484M | 0.18% |
51ARVN | ARVINAS INC | Healthcare | $450M | 0.17% |
52AVTX | AVALO THERAPEUTICS INC | Healthcare | $445M | 0.17% |
53PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.16% |
54LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $385M | 0.14% |
55ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $326M | 0.12% |
56AGEN | AGENUS INC | Healthcare | $311M | 0.12% |
57EVMN | EVOMMUNE INC | Healthcare | $291M | 0.11% |
58QTTB | Q32 BIO INC | Healthcare | $264M | 0.10% |
59BIOA | BIOAGE LABS INC | Healthcare | $260M | 0.10% |
60ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.09% |
61DTIL | PRECISION BIOSCIENCES INC | Healthcare | $225M | 0.08% |
62TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.08% |
63KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.07% |
64KRRO | KORRO BIO INC | Healthcare | $196M | 0.07% |
65RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.07% |
66STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.06% |
67CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.05% |
68RLYB | RALLYBIO CORP | Healthcare | $84M | 0.03% |
69VTVT | VTV THERAPEUTICS INC | Healthcare | $83M | 0.03% |
70GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.03% |
71XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.02% |
72YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.02% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $265.50B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 85% toward Large, 54% toward Growth. +5% unclassified (7 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 72 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T063725 rates=20261113T063725
Measured on the 2026-11 formation date across 72 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators disagree about the verdict, not just the value — the choice of method decides the answer here. Historical VaR gives ratio 1.88 (pass) but Gaussian VaR gives 2.16 (fail). The pass/fail conclusion is an artefact of estimator choice, not a property of the strategy.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Publication date unknown. We don’t have a source year for this signal, so we can’t split its record into before and since publication. That’s a gap in our reference data — not a statement about how the factor performed.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 15.9% | -10.8% |
| 3 yearsp.a. | 26.4% | 17.9% |
| 5 yearsp.a. | 5.0% | -1.7% |
| 10 yearsp.a. | 17.4% | 5.6% |
| Since inceptionp.a. | 13.7% | 2.6% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 19.6% | -9.7% |
| 2025 | 51.7% | 51.8% |
| 2024 | -7.5% | 1.0% |
| 2023 | 18.2% | 14.5% |
| 2022 | -33.1% | -31.3% |
| 2021 | -8.5% | -33.4% |
| 2020 | 83.9% | 62.4% |
| 2019 | 71.2% | 45.4% |
| 2018 | -4.2% | -8.6% |
| 2017 | 45.0% | 17.0% |
| 2016 | -32.3% | -29.8% |
| 2015 | 2.0% | -4.7% |
| 2014 | 22.3% | -4.0% |
| 2013 | 62.3% | 12.0% |
| 2012 | 40.1% | 22.7% |
| 2011 | 4.4% | -11.5% |
| 2010 | 21.1% | 6.5% |
| 2009 | 15.4% | -12.7% |
| 2008 | 1.3% | 68.9% |
| 2007 | -8.0% | -21.7% |
| 2006 | -3.9% | -2.6% |
| 2005 | 7.5% | -19.1% |
| 2004 | 7.0% | -18.8% |
| 2003 | 26.0% | -6.6% |
| 2002 | -38.3% | -29.0% |
| 2001 | -18.8% | -10.0% |
| 2000 | 75.5% | 4.2% |
| 1999 | 110.5% | 190.6% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Gross Margin Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Gross Margin signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.